Quality Assurance of Pharmaceuticals - A Compendium of Guidelines and Related Materials - Volume 1
(1997; 248 pages) [French] View the PDF document
Table of Contents
Open this folder and view contentsIntroduction
Open this folder and view contents1. National drug regulation
Open this folder and view contents2. Product assessment and registration
Open this folder and view contents3. Distribution
Open this folder and view contents4. The international pharmacopoeia and related activities
Open this folder and view contents5. Basic tests
Close this folder6. Laboratory services
Open this folder and view contentsNational laboratories for drug quality surveillance and control1
Open this folder and view contentsGood laboratory practices in governmental drug control laboratories1
Close this folderSampling procedure for industrially manufactured pharmaceuticals1
Open this folder and view contents1. General considerations
Open this folder and view contents2. Use of terms
View the document3. General precautions to be taken during sampling operations
View the document4. Packaging and labelling of samples
View the document5. Sampling during pharmaceutical inspections
View the document6. Sampling of pharmaceutical dosage forms in regular surveillance programmes on drug quality during marketing
View the document7. Sampling of pharmaceutical dosage forms for acceptance of consignments
Open this folder and view contents8. Sampling of starting materials
Open this folder and view contents7. International trade in pharmaceuticals
Open this folder and view contents8. Counterfeit products
Open this folder and view contents9. Training
View the documentSelected WHO publications of related interest
View the documentBack cover
 

6. Sampling of pharmaceutical dosage forms in regular surveillance programmes on drug quality during marketing

National drug control authorities hold the responsibility to monitor the quality of all drug products marketed in the territory of their competence. The extent to which routine surveillance, as opposed to assessment of suspect products, should be undertaken will depend upon the capacity of the national quality-control laboratory, the extent to which the quality of products is assessed prior to registration, the extent to which the requirements for good manufacturing practice are implemented, and the number of products that are imported from abroad.

A systematic programme of drug quality surveillance should aim at regular sampling of all marketed products whether registered for sale or compounded in pharmacies. Each product should be assessed at least once every two to three years, but particular attention should be accorded to products that are of prime importance to public health programmes or that are potentially dangerous, unstable, or difficult to formulate properly.

The programme of sampling should be drawn up by the responsible laboratory, if necessary under the guidance of the drug control authority, on a yearly or half-yearly basis. This programme should not only list the products to be sampled during a given period, but should also specify the sampling procedures and the size of the samples to be collected, taking into account the need for retention samples. The programme should determine to what extent each brand of a given product will be sampled and which local authority or inspector will be responsible for each sampling operation, and it should indicate to which laboratory (if more than one exists) each sample should be sent. Such a programme enables the facilities of each laboratory to be used to best advantage.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014